Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Top Cited Papers
Publisher Website
Google Scholar
Abstract
Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).1 The durability of protection is currently unknown. We describe mRNA1273-elicited binding and neutralizing antibodies in 33 healthy adult participants in an ongoing phase 1 trial,2-4 stratified according to age, at 180 days after the second dose of 100 μg (day 209).
Funding Information
  • Covid-Catalyst-I3 Funds from the Woodruff Health Sciences Center and Emory School of Medicine
  • North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill
  • North Carolina Coronavirus Relief Fund
  • Coalition for Epidemic Preparedness Innovations
  • Georgia Research Alliance
  • National Institute of Allergy and Infectious Diseases (AI149644, HHSN272201500002C, P51 OD011132, UM1AI148373, UM1AI148576, UM1AI148684, UM1Al148684-01S1)
  • National Center for Advancing Translational Sciences (UL1 TR002243)
  • Dolly Parton COVID-19 Research Fund
  • Emory Executive Vice President for Health Affairs Synergy Fund award
  • Center for Childhood Infections and Vaccines
  • Children’s Healthcare of Atlanta

This publication has 5 references indexed in Scilit: